ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1370	National Cancer Institute	Html	en	Colorectal Cancer Screening (PDQ®)–Health Professional Version	Expert-reviewed information summary about tests used to detect or screen for colorectal cancer.	adenomas 0.617512 advanced proximal neoplasia 0.563212 study 0.677803 mortality reduction 0.57851 advanced neoplasia 0.56302 CRC mortality reduction 0.544829 colonoscopy screening 0.603021 lesions 0.531993 occult blood screening 0.64042 CRC mortality difference 0.548807 CRC incidence rates 0.553335 Engl J Med 0.6404 CRC mortality 0.70138 CRC cases 0.529979 annual FOBT screening 0.529584 faecal occult blood 0.779217 Ann Intern Med 0.763728 complete colonoscopy 0.535099 colorectal cancer screening 0.676312 colonoscopy 0.785471 positive test 0.545148 colorectal neoplasia 0.540206 colorectal cancer incidence 0.537416 detection 0.55517	colorectal cancer 0.99103 CRC screening 0.62285 Abstract 0.639242 Screening Colonoscopy Program 0.575204 patients 0.584805 occult blood testing 0.542273 colonoscopy study 0.538236 CRC incidence 0.62219 systematic review 0.578714 lower CRC mortality 0.560554 virtual colonoscopy 0.591165 CRC screening program 0.568518 FIT 0.57064 Colorectal cancer mortality 0.560865 negative colonoscopy results 0.549077 concurrently performed colonoscopy 0.531966 fecal occult blood 0.884171 CRC 0.781593 sigmoidoscopy versus colonoscopy 0.551587 colorectal cancer diagnosis 0.530522 distal colon 0.542283 occult blood test 0.71312 sensitivity 0.537205	CLICK HERE
1406	National Cancer Institute	Html	en	Endometrial Cancer Screening (PDQ®)–Health Professional Version	Expert-reviewed information summary about tests used to detect or screen for endometrial cancer.	underwent endometrial biopsy 0.596006 exhibit similar risk 0.466243 endometrial thickness cutoff 0.594653 endometrial carcinoma 0.559295 asymptomatic women 0.56298 markedly increased risk 0.46896 endometrial biopsy 0.602665 TVU 0.506165 threshold value 0.468657 postmenopausal uterine bleeding 0.47677 hormone therapy study 0.462599 postmenopausal hormone therapy. 0.491288 additional risk factors 0.461801 endometrial cavity access. 0.584206 high survival rates 0.463126 lower survival rates 0.458386 endometrial thickness 0.608159 endometrial hyperplasia 0.560125 white women 0.528892 combination estrogen-progesterone therapy 0.467831 endometrial cancer 0.93723 U.S. women 0.465931 abnormal pathologic biopsy 0.461543 black women 0.483703 women 0.713028	unopposed estrogen therapy 0.4738 endometrial cancer. 0.591335 nonpolyposis colorectal cancer 0.479683 endometrial polyps 0.561278 endometrial aspiration 0.621101 Measuring endometrial thickness 0.597601 estrogen therapy 0.49246 Cancer Survival Study 0.480563 tamoxifen increase patients 0.459307 National Cancer Institute 0.477348 hormone therapy 0.561237 endometrial biopsy specimens 0.590423 endometrial cancer incidence 0.661899 African American women 0.535123 invasive gynecologic cancer 0.486102 advanced-stage disease 0.478186 breast cancer 0.469124 asymptomatic postmenopausal women 0.5655 primary endometrial cancer 0.608017 Project P-1 trial 0.458556 endometrial abnormalities 0.576298 National Surgical Adjuvant 0.459038 African American women. 0.461116 mean age 0.461702	CLICK HERE
1450	National Cancer Institute	Html	en	Esophageal Cancer Screening (PDQ®)–Health Professional Version	Expert-reviewed information summary about tests used to detect or screen for esophageal cancer.	population-based case-controlled study 0.533968 symptomatic gastroesophageal reflux 0.581421 columnar-lined esophagus 0.552922 curable neoplasms 0.466702 Barrett esophagus 0.931446 Gastric cardia adenocarcinoma 0.596066 lower esophageal sphincter 0.581561 standard histological evaluation 0.515998 gastroesophageal reflux 0.731721 squamous cell cancer 0.550703 surveillance method 0.472755 risk factors 0.526039 annual endoscopy 0.479023 esophageal squamous cell 0.594095 gastric acid production 0.530474 -relaxing drugs 0.467279 patients 0.488679 Barrett esophagus. 0.572924 GERD 0.55771 esophageal cancer incidence 0.58939 esophageal adenocarcinoma 0.818574 esophageal adenocarcinoma. 0.53156 human papillomavirus 0.478898 new cases 0.479464	gastroesophageal reflux disease 0.686421 low risk 0.472905 esophageal cancer 0.594243 H. pylori infections 0.535834 infection persisted. 0.473995 incidence rate ratio 0.524115 reflux esophagitis 0.501118 surgical resection 0.524265 low-grade dysplasia 0.493637 effective surveillance protocol 0.524901 surveillance endoscopy 0.490968 reflux symptoms 0.502651 high-grade dysplasia 0.535845 important epidemiological difference 0.530091 strong association 0.468389 expert gastrointestinal endoscopists 0.517855 duodenal ulcers 0.473231 risk factor 0.481047 Western countries 0.470134 successful resection 0.474238 cancer mortality. 0.469146 gastric infection 0.4806 risk 0.536679 intramucosal carcinoma 0.47033	CLICK HERE
1510	National Cancer Institute	Html	en	Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of small cell lung cancer.	Lung Cancer Cooperative 0.39126 small-cell lung cancer 0.985475 European Lung Cancer 0.390681 chemotherapy 0.385408 Engl J Med 0.425383 American Cancer Society 0.349857 Br J Cancer 0.382857 limited-stage small-cell lung 0.52446 Lung cancer deaths 0.390773 tobacco-specific lung carcinogen 0.37583 Lung Oncology Group 0.359221 Radiat Oncol Biol 0.383871 Lung Cancer Group 0.384497 oncology group study 0.36864 poor-prognosis small-cell lung 0.365771 Natl Cancer Inst 0.372388 cancer research campaign 0.352725 Council Lung Cancer 0.415558 stage small-cell lung 0.379153 Medical Research Council 0.386248 small-cell lung carcinoma 0.374311 et al. 0.448513 Lung Cancer Working 0.375734 extensive-disease small-cell lung 0.370168 Research Council Lung 0.400238	Cancer Epidemiol Biomarkers 0.349186 PUBMED Abstract 0.373095 limited-disease small-cell lung 0.382414 extensive small-cell lung 0.411565 limited-stage small cell 0.350265 small cell lung 0.655538 prophylactic cranial irradiation 0.394396 disease small-cell lung 0.396424 extensive-stage small-cell lung 0.398504 lung cancer patients 0.41432 Cancer Lung Cancer 0.412017 Abstract 0.488813 Clin Oncol 0.605439 cell lung carcinoma 0.379947 Oncol Biol Phys 0.385351 untreated small-cell lung 0.364584 lung cancer risk 0.385828 advanced small-cell lung 0.364607 Low-dose lung 0.356029 cell lung cancer 0.62237 better-prognosis small-cell lung 0.365507 multiple lung nodules 0.359952 thoracic radiotherapy 0.411609 limited small-cell lung 0.423802	CLICK HERE
1529	National Cancer Institute	Html	en	Male Breast Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of male breast cancer.	Clinical breast exam 0.284327 Breast Cancer Screening 0.314882 breast duct 0.265624 cancer spreads 0.259464 diagnose breast cancer 0.343362 malignant tumor cells 0.26356 body 0.314871 PDQ cancer information 0.299069 Inflammatory Male Breast 0.288019 clinical trials 0.336788 breast cancer stage 0.313107 cancer information summary 0.28338 clinical trial 0.259026 breast cancer prevention 0.329746 breast cancer patients 0.302243 lymph node biopsy 0.306018 sentinel lymph node 0.33726 Inflammatory breast cancer 0.359802 NCI PDQ cancer 0.260729 early localized breast 0.2726 lymph nodes 0.375271 breast carcinoma 0.267321 metastatic breast cancer 0.413709 radiation therapy 0.324944 treatment 0.354882	abnormal cells 0.280815 male breast cancer 0.548303 cancer cells 0.507692 Cancer Information Service 0.257721 specific cancer cells 0.266994 breast cancers 0.260852 National Cancer Institute 0.306996 Breast Cancer Treatment 0.32856 hormone therapy 0.286562 painful breast lesions 0.269444 lymph vessels 0.259581 new treatment 0.256083 breast cancer cells 0.328644 breast cancer 0.95341 Hereditary breast cancer 0.321208 chest wall 0.263619 Recurrent breast cancer 0.304665 IIIC breast cancer 0.305672 tumor 0.317659 treatment options 0.26574 cancer information summaries 0.256227 comprehensive cancer information 0.256173 information 0.313083 appropriate cancer treatment 0.261896	CLICK HERE
1572	National Cancer Institute	Html	en	Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Screening (PDQ®)–Patient Version	Expert-reviewed information summary about tests used to detect or screen for ovarian, fallopian tube, and primary peritoneal cancers.	cancer treatment 0.488772 primary peritoneal cancers 0.500293 ongoing clinical trials 0.488493 following PDQ summaries 0.549415 PDQ cancer information 0.706697 false-negative test result 0.485124 fallopian tube cancer 0.565282 primary peritoneal cancer 0.815712 clinical trials 0.639646 test result 0.547906 Peritoneal Cancer Prevention 0.54551 cancer information summary 0.620799 PDQ Ovarian 0.537752 clinical trial 0.497999 breast cancer prevention 0.513915 ovarian cancer 0.852752 false-positive test result 0.536437 cancer patients 0.484043 latest published information 0.494395 peritoneal cancer form 0.545913 NCI’s PDQ 0.505993 cancer symptoms 0.504824 NCI PDQ cancer 0.581936 tests 0.532273	certain types 0.48682 black women 0.481021 PDQ Screening 0.526415 peritoneal cancer screening 0.608486 cancer prevention 0.549601 screening tests 0.485985 Cancer Information Service 0.531657 fallopian tube 0.68704 Prevention Editorial Board 0.543082 treatment clinical trials 0.485965 National Cancer Institute 0.650104 PDQ documents 0.496817 cancer doctors 0.479641 new treatment 0.493333 Cancer screening trials 0.564141 Ovarian epithelial cancer 0.582644 Cancer Care page 0.517342 PDQ database 0.501449 PDQ summary 0.536253 fallopian tubes 0.578652 cancer information summaries 0.539976 health professional versions 0.477788 comprehensive cancer information 0.539707 cancer 0.983489	CLICK HERE
1593	National Cancer Institute	Html	en	Mistletoe Extracts (PDQ®)–Health Professional Version	Mistletoe, a semiparasitic plant that grows on several types of trees such as apple, oak, pine and elm, is commonly used in cancer patients in Europe. Read about laboratory and human studies of extracts, such as Iscador and Eurixor, and their effects on quality of life, survival and symptom relief in this expert-reviewed summary.	aqueous mistletoe extract 0.442009 mistletoe lectin-1-standardized extract 0.441439 mistletoe extracts 0.647935 recombinant mistletoe lectin 0.458451 Viscum album var. 0.395649 viscum album 0.915234 viscum album extracts 0.415076 Viscum album L. 0.758622 mistletoe preparations 0.534599 orally administered mistletoe 0.439154 breast cancer patients 0.419485 galactoside-specific mistletoe lectin 0.506693 patients 0.47671 cancer patients 0.474171 mistletoe 0.798357 lectin standardized mistletoe 0.506505 galactoside-specific lectin 0.442636 galactoside-binding mistletoe lectin 0.510133 adjuvant mistletoe treatment 0.475546 mistletoe lectin-induced apoptosis 0.437043 mistletoe treatment programme 0.472546 et al. 0.450682 mistletoe lectin ML-1 0.486886 Korean mistletoe lectin 0.477775	mistletoe treatment 0.507798 PUBMED Abstract 0.60337 mistletoe extract 0.555931 Purified mistletoe lectins 0.438108 Viscum album extract 0.453589 different mistletoe preparations 0.423047 Anticancer Res 0.416126 galactoside-specific mistletoe lectin-1 0.433265 mistletoe’s ability 0.439494 blood mononuclear cells 0.426242 standardized mistletoe extracts 0.436989 Gabius HJ 0.430845 European mistletoe 0.545426 mistletoe lectin-II-induced apoptosis 0.4369 breast cancer 0.430552 aqueous mistletoe preparations 0.463767 mistletoe lectins 0.543537 Viscum album preparation 0.39341 unfermented mistletoe preparations 0.438537 iscador 0.417024 mistletoe extract Iscar 0.429817 mistletoe lectin 0.642042 cancer 0.50332 standardized mistletoe extract 0.492996	CLICK HERE
1886	National Cancer Institute	Html	es	Tratamiento de la micosis fungoide (incluso el síndrome de Sézary) (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la micosis fungoide (incluso el síndrome de Sézary).	mycosis fungoides patients 0.11169 with cutaneous t-cell 0.128234 Dummer R 0.111348 Syndrome With Variable 0.114584 mycosis fungoides 0.97928 beam therapy with 0.111374 mycosis fungoides with 0.131223 patients with refractory 0.123614 patients with mycosis 0.138673 refractory mycosis fungoides 0.123051 Sézary Syndrome With 0.116656 lymphomas with cutaneous 0.112178 Am Acad Dermatol 0.337245 Cutaneous Lymphoma Consortium 0.148918 Lymphoma Study Group 0.112378 cutaneous lymphoma 0.228697 fungoides with twice-weekly 0.112255 Radiat Oncol Biol 0.152639 treatment refractory cutaneous 0.111862 with erythrodermic cutaneous 0.112109 Hematol Oncol Clin 0.121844 United States Cutaneous 0.120966 cutaneous lymphoma international 0.128062 patients with 0.427189 Total skin 0.115055	patients treated with 0.1213 with cutaneous 0.12999 Arch Dermatol 0.198688 cutaneous t-cell lymphoma 0.78168 with refractory cutaneous 0.113675 States Cutaneous Lymphoma 0.140249 Duvic M 0.128091 Kim YH 0.150166 with cutaneous manifestations 0.111847 initial treatment 0.113809 sézary syndrome 0.418227 T-cell lymphomas with 0.111442 refractory cutaneous t-cell 0.128365 Lymphoma Myeloma Leuk 0.11766 fungoides with photochemotherapy 0.112499 Guitart J 0.113207 Clin Oncol 0.349784 lymphoma international prognostic 0.112345 Oncol Biol Phys 0.155154 patients with cutaneous 0.128063 Clin North Am 0.119374 Lymphoma International Consortium 0.112352 Oncol Clin North 0.121296 Zackheim HS 0.112943	CLICK HERE
3448	National Cancer Institute	Html	es	Prevención del cáncer de ano (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de ano, y sobre las investigaciones dirigidas a la prevención de esta enfermedad.	Malignancies Among Cancer 0.376997 long-term risk 0.317273 lesiones precursoras 0.331467 Goldstone S 0.318721 American Cancer Society 0.336812 NIH Pub 0.338006 Giuliano AR 0.319633 CA Cancer 0.335938 Engels EA 0.334211 nationwide cohort study 0.318123 Second cancers among 0.32229 new malignancies 0.372644 Frisch M 0.318875 anal hpv 0.38502 Ron E 0.319704 risk factors 0.340585 anal intraepithelial neoplasia 0.348272 Natl Cancer Inst 0.37761 papillomavirus-related gynecologic neoplasm 0.319719 cancers among 0.324258 human papillomavirus 0.471776 Anal carcinoma 0.320142 Cancer Epidemiology 0.319322 hpv infection 0.344517 SEER Cancer Statistics 0.322144	have sex with 0.39684 cohort study 0.328375 who have sex 0.393593 anal intra-epithelial neoplasia 0.321943 Fraumeni JF Jr 0.315722 Madeleine MM 0.330833 SEER Cancer 0.386157 SEER Cancer Registries 0.37953 Infect Dis 0.350074 Cancer Facts 0.318636 Curtis RE 0.320735 New Malignancies Among 0.340351 National Cancer Institute 0.584605 among men 0.315549 características histológicas 0.334238 Among Cancer Survivors 0.378869 papillomavirus-associated anal cancers 0.323075 Palefsky JM 0.334575 Freedman DM 0.321699 Cancer Survival Among 0.320203 anal cancer 0.954929 New malignancies following 0.338599 sexual practices 0.336294 cuello uterino 0.534342	CLICK HERE
3563	National Cancer Institute	Html	en	Jonathan S. Wiest, Ph.D.	Dr. Jonathan S. Wiest obtained a bachelor’s degree in analytical chemistry from the University of Wisconsin-Milwaukee in 1980.	North Carolina 0.409045 Wisconsin-Milwaukee 0.254953 Merit 0.234346 Cincinnati 0.232275 Associate Director 0.407274 lung cancer 0.424227 tumor suppressor genes 0.574882 Department 0.23225 major training activities 0.564519 Ph.D. 0.233553 Jonathan S. Wiest 0.863013 Distinguished Service Award 0.551249 graduate school 0.424709 rank 0.235426 Dr. Wiest 0.997677 Senior Staff Fellow 0.581562 Environmental Health 0.594668 National Postdoctoral Association 0.552911 P-L Biochemicals 0.44241 Cancer Training 0.545462 degree 0.236458 pathways 0.234519 oligonucleotides 0.254305 major focus 0.390603	University 0.266416 Research Triangle Park 0.595619 lung tumorigenesis 0.406774 Environmental Health Sciences 0.585151 analytical chemistry 0.428974 Cancer Research Institute 0.616451 annual meeting 0.38327 National Cancer Institute 0.597756 NCI Outstanding Mentor 0.614163 production chemist 0.439071 assistant professor 0.400629 National Institute 0.418588 western Colorado 0.405661 Center 0.289661 bachelor 0.23726 NCI Director 0.467597 genetic alterations 0.402361 Medical College 0.424659 extramural communities 0.42187 NIH Director 0.428955 CCT 0.328048 Ohio 0.235704 Toledo 0.23553 NIH Award 0.427672	CLICK HERE